Terms: = Brain cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K AND Clinical Outcome
23 results:
1. The Role of Activation of pi3k/AKT/mTOR and RAF/MEK/ERK Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract] [Full Text] [Related]
2. Molecular and clinical diversity in primary central nervous system lymphoma.
Hernández-Verdin I; Kirasic E; Wienand K; Mokhtari K; Eimer S; Loiseau H; Rousseau A; Paillassa J; Ahle G; Lerintiu F; Uro-Coste E; Oberic L; Figarella-Branger D; Chinot O; Gauchotte G; Taillandier L; Marolleau JP; Polivka M; Adam C; Ursu R; Schmitt A; Barillot N; Nichelli L; Lozano-Sánchez F; Ibañez-Juliá MJ; Peyre M; Mathon B; Abada Y; Charlotte F; Davi F; Stewart C; de Reyniès A; Choquet S; Soussain C; Houillier C; Chapuy B; Hoang-Xuan K; Alentorn A
Ann Oncol; 2023 Feb; 34(2):186-199. PubMed ID: 36402300
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S; Solomon DA; Perez E; Thieme A; Kleinschmidt-DeMasters BK; Giannini C; Reinhardt A; Asa SL; Mete O; Stichel D; Siewert C; Dittmayer C; Hasselblatt M; Paulus W; Nagel C; Harter PN; Schittenhelm J; Honegger J; Rushing E; Coras R; Pfister SM; Buslei R; Koch A; Perry A; Jones DTW; von Deimling A; Capper D; Lopes MB
Acta Neuropathol; 2021 Dec; 142(6):1025-1043. PubMed ID: 34661724
[TBL] [Abstract] [Full Text] [Related]
4. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract] [Full Text] [Related]
5. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating pi3k/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract] [Full Text] [Related]
6. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer.
Machado-Rugolo J; Fabro AT; Ascheri D; Farhat C; Ab'Saber AM; de Sá VK; Nagai MA; Takagaki T; Terra R; Parra ER; Capelozzi VL
Hum Pathol; 2019 Jan; 83():177-191. PubMed ID: 30218756
[TBL] [Abstract] [Full Text] [Related]
7. Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.
Wu HB; Yang S; Weng HY; Chen Q; Zhao XL; Fu WJ; Niu Q; Ping YF; Wang JM; Zhang X; Yao XH; Bian XW
Autophagy; 2017 Sep; 13(9):1528-1542. PubMed ID: 28812437
[TBL] [Abstract] [Full Text] [Related]
8. Tracking the Evolution of Non-Small-Cell Lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
9. Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via pi3k/Akt signaling in glioma.
Song Y; Zheng S; Wang J; Long H; Fang L; Wang G; Li Z; Que T; Liu Y; Li Y; Zhang X; Fang W; Qi S
Oncotarget; 2017 Jun; 8(26):41947-41962. PubMed ID: 28410212
[TBL] [Abstract] [Full Text] [Related]
10. TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.
Hill R; Madureira PA; Ferreira B; Baptista I; Machado S; Colaço L; Dos Santos M; Liu N; Dopazo A; Ugurel S; Adrienn A; Kiss-Toth E; Isbilen M; Gure AO; Link W
Nat Commun; 2017 Mar; 8():14687. PubMed ID: 28276427
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic Potentials of BDNF/TrkB in Breast cancer; Current Status and Perspectives.
Tajbakhsh A; Mokhtari-Zaer A; Rezaee M; Afzaljavan F; Rivandi M; Hassanian SM; Ferns GA; Pasdar A; Avan A
J Cell Biochem; 2017 Sep; 118(9):2502-2515. PubMed ID: 28230291
[TBL] [Abstract] [Full Text] [Related]
12. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional pi3k inhibition.
Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
[TBL] [Abstract] [Full Text] [Related]
13. AKT/GSK3β Signaling in Glioblastoma.
Majewska E; Szeliga M
Neurochem Res; 2017 Mar; 42(3):918-924. PubMed ID: 27568206
[TBL] [Abstract] [Full Text] [Related]
14. Phase II study of PX-866 in recurrent glioblastoma.
Pitz MW; Eisenhauer EA; MacNeil MV; Thiessen B; Easaw JC; Macdonald DR; Eisenstat DD; Kakumanu AS; Salim M; Chalchal H; Squire J; Tsao MS; Kamel-Reid S; Banerji S; Tu D; Powers J; Hausman DF; Mason WP
Neuro Oncol; 2015 Sep; 17(9):1270-4. PubMed ID: 25605819
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of colorectal cancer pik3ca mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract] [Full Text] [Related]
16. Molecular interactions of ErbB1 (EGFR) and integrin-β1 in astrocytoma frozen sections predict clinical outcome and correlate with Akt-mediated in vitro radioresistance.
Petrás M; Lajtos T; Friedländer E; Klekner A; Pintye E; Feuerstein BG; Szöllosi J; Vereb G
Neuro Oncol; 2013 Aug; 15(8):1027-40. PubMed ID: 23595626
[TBL] [Abstract] [Full Text] [Related]
17. PTEN promoter methylation and activation of the pi3k/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
[TBL] [Abstract] [Full Text] [Related]
18. A distinct spectrum of copy number aberrations in pediatric high-grade gliomas.
Bax DA; Mackay A; Little SE; Carvalho D; Viana-Pereira M; Tamber N; Grigoriadis AE; Ashworth A; Reis RM; Ellison DW; Al-Sarraj S; Hargrave D; Jones C
Clin Cancer Res; 2010 Jul; 16(13):3368-77. PubMed ID: 20570930
[TBL] [Abstract] [Full Text] [Related]
19. Molecular profiling in glioblastoma: prelude to personalized treatment.
Mladkova N; Chakravarti A
Curr Oncol Rep; 2009 Jan; 11(1):53-61. PubMed ID: 19080742
[TBL] [Abstract] [Full Text] [Related]
20. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis.
Opel D; Westhoff MA; Bender A; Braun V; Debatin KM; Fulda S
Cancer Res; 2008 Aug; 68(15):6271-80. PubMed ID: 18676851
[TBL] [Abstract] [Full Text] [Related]
[Next]
